Showing results (111-120 of 143) with videos related to
Sort By:
Pageof 15
Cancer Research|July 15, 1993
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780N Brünner, T L Frandsen, C Holst-Hansen, et al.Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|January 24, 2003
Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasisH J Nielsen, I J Christensen, M N Svendsen, et al.Journal of Immunological Methods|April 11, 1997
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISAA N Pedersen, G Høyer-Hansen, N Brünner, et al.Anticancer Research|April 1, 2009
Changes in plasma TIMP-1 levels after resection for primary colorectal cancerC Frederiksen, A F Lomholt, G J Davis, et al.Breast Cancer Research and Treatment|March 1, 1995
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodiesE Rønne, G Høyer-Hansen, N Brünner, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|June 23, 1999
Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevanceC F Sier, N Sidenius, A Mariani, et al.European Journal of Cancer & Clinical Oncology|July 1, 1985
Characterization of the T61 human breast carcinoma established in nude miceN Brünner, G B Bastert, H S Poulsen, et al.Clinical & Experimental Metastasis|January 1, 1993
The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cellsE W Thompson, N Brünner, J Torri, et al.Breast Cancer Research and Treatment|December 1, 2001
Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastatC Holst-Hansen, J A Low, R W Stephens, et al.Cancer Research|May 15, 1998
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patientsC F Sier, R Stephens, J Bizik, et al.Pageof 15